PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsArsenic trioxide
Trisenox(arsenic trioxide)
Arsenic Trioxide, Trisenox (arsenic trioxide) is a small molecule pharmaceutical. Arsenic trioxide was first approved as Trisenox on 2000-09-25. It is used to treat promyelocytic leukemia acute in the USA. It has been approved in Europe to treat promyelocytic leukemia acute.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
Trade Name
FDA
EMA
Arsenic trioxide, Trisenox (discontinued: Arsenic trioxide, Trisenox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Arsenic trioxide
Tradename
Company
Number
Date
Products
TRISENOXCephalonN-021248 RX2017-10-13
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
arsenic trioxideANDA2025-08-21
trisenoxNew Drug Application2023-09-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
promyelocytic leukemia acute—D015473C92.4
Agency Specific
FDA
EMA
Expiration
Code
ARSENIC TRIOXIDE, TRISENOX, CEPHALON
2025-01-12ODE-167
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX27: Arsenic trioxide
HCPCS
Code
Description
J9017
Injection, arsenic trioxide, 1 mg
Clinical
Clinical Trials
151 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Promyelocytic leukemia acuteD015473—C92.4——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9511———2
Myeloid leukemiaD007951—C9211———2
Myelodysplastic syndromesD009190—D46—1———1
Myeloid leukemia acuteD015470—C92.0—1———1
Myelomonocytic leukemia chronicD015477—C93.1—1———1
Myelomonocytic leukemia juvenileD054429—C93.3—1———1
PreleukemiaD011289———1———1
Lung neoplasmsD008175—C34.90—1———1
Small cell carcinomaD018288———1———1
Small cell lung carcinomaD055752———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameArsenic trioxide
INN—
Description
Arsenic trioxide, sold under the brand name Trisenox among others, is an inorganic compound with the formula As2O3. As an industrial chemical, its major uses include the manufacture of wood preservatives, pesticides, and glass. It is also used as a medication to treat a type of cancer known as acute promyelocytic leukemia. For this use it is given by injection into a vein.
Classification
Small molecule
Drug classAntineoplastic agent
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O1[As]2O[As]3O[As]1O[As](O2)O3
Identifiers
PDB—
CAS-ID1327-53-3
RxCUI—
ChEMBL IDCHEMBL2362016
ChEBI ID30621
PubChem CID261004
DrugBankDB01169
UNII ID—
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,713 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arsenic trioxide, Trisenox
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,414 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use